I have been through one internal appeal already and would like to do the next one properly.
I have the document in front of me and I can read the numbers. What I cannot do is interpret them.
I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.
What does this actually establish, and what does it not?
Section 503A is an exemption, not an approval, and it is conditional on four things. A patient-specific prescription; a licensed pharmacist or physician doing the compounding in a licensed facility; bulk substances that either have a USP monograph, appear on the FDA's 503A bulks list, or are components of an approved drug, each with a certificate of analysis from a registered supplier; and the preparation must not be essentially a copy of a commercially available drug. That last condition is the one that moves: it turns on the shortage list, and what was lawful under 503A while a product was in shortage stops being lawful when the shortage is resolved. None of the four requires the finished preparation to be tested, which is the gap that independent assay fills.
Answer first: the two categories differ in whether a prescription for a named patient is required and in which quality standards apply, and that difference decides everything downstream.
The practical consequences: an outsourcing facility can supply office stock and distribute at volume; a patient-specific compounder cannot do either without stepping outside its category.
The part that matters: beyond-use dating differs by category and by the preparation environment, and an unusually long date on a compounded sterile preparation is worth asking about.
Adverse event reporting obligations attach to registered outsourcing facilities and are the basis for what public information exists.
This structure is jurisdiction-specific. It does not describe your country unless it does.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThe relevant point is that the heavier-obligation category is inspected against manufacturing standards and the lighter one is not.
Patient-specific compounding requires a prescription for a named individual, is regulated primarily at state level, and is not subject to current good manufacturing practice requirements.
The underlying point is that registration status is published and searchable. Checking it takes a minute and is the single most useful verification available in this whole area.
Inspection findings for registered facilities are published and are directly checkable for a named facility.
Neither category is an approved product. That is unchanged by registration.
edited 4 Dec 2025 by kelvin_lam — fixed an arithmetic slip in the third paragraph
The short version: patient-specific compounding under one framework, office-stock production under the other, with much heavier obligations on the second.
A facility that will not say which category it operates under has told you something, and the registration lists will tell you the rest.
Outsourcing facilities may produce without a patient-specific prescription, register federally, are inspected on a risk-based schedule and are subject to current good manufacturing practice.
The two-tier structure separating patient-specific compounding from outsourcing facilities is established in federal law and the registration lists are published.
Inspection findings are public for registered facilities. Read them.
edited 5 Nov 2025 by gradient_slope — reworded for clarity after a comment
Start with which category a facility is registered under, because it is a matter of public record and it tells you what it can legally do.
Neither category produces an approved product. Both operate outside the marketing-authorisation framework, and the difference is in the manufacturing standards applied, not in approval status.
Current good manufacturing practice applies to the outsourcing category and not to patient-specific compounding, which is the substantive regulatory difference.
A registration category describes obligations, not the quality of any particular preparation.
The category tells you which standards apply, not how good the preparation is.
The honest answer is that the category tells you about obligations rather than about the quality of any particular preparation.
Adverse event reporting obligations attach to the outsourcing category and not to the patient-specific one, which is a real difference in the information that exists about what a facility produces.
Nothing here is legal or medical advice.
Check the registration list. It takes a minute and it is the one verifiable claim here.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.